Literature DB >> 18275155

ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.

Gregory Tombline1, Jason J Holt, Michael K Gannon, David J Donnelly, Bryan Wetzel, Geri A Sawada, Thomas J Raub, Michael R Detty.   

Abstract

The multidrug efflux pump P-glycoprotein (Pgp) couples drug transport to ATP hydrolysis. Previously, using a synthetic library of tetramethylrosamine ( TMR) analogues, we observed significant variation in ATPase stimulation ( V m (D)). Concentrations required for half-maximal ATPase stimulation ( K m (D)) correlated with ATP hydrolysis transition-state stabilization and ATP occlusion (EC 50 (D)) at a single site. Herein, we characterize several TMR analogues that elicit modest turnover ( k cat <or= 1-2 s (-1)) compared to verapamil (VER) ( k cat approximately 10 s (-1)). Apparent ATPase activities manifest as nearly equivalent to basal values. In some cases, K m (D) parameters for drug stimulation of ATPase could not be accurately determined, yet these same TMR analogues promoted ATP occlusion at relatively low concentrations ( approximately 0.4-40 microM). Moreover, the TMR analogues competitively inhibited VER-dependent ATPase activity at concentrations similar to those required for ATP occlusion. Finally, the TMR analogues facilitated uptake of calcein-AM into CR1R12 and MDCK-MDR1 cells and are actively transported by Pgp in monolayers of MDCK-MDR1 cells at similarly low concentrations ( approximately 1-20 microM). ADP.V i release kinetics were identical in the presence of the TMR derivatives, VER, or in the absence of drug, suggesting that slow turnover is not likely due to slow release of the ATP hydrolysis products ADP and P i. These data support the partition model in which drug site occupancy converts residual basal ATPase activity to a drug-dependent mechanism even in cases where stimulation appears to be exactly compensatory to basal values. It is noteworthy that when compared to previously reported TMR analogues, subtle modification of the TMR scaffold can confer large differences in ATP turnover.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275155     DOI: 10.1021/bi7021393

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1).

Authors:  Alexandra Orchard; Gregory A Schamerhorn; Brandon D Calitree; Geri A Sawada; Tip W Loo; M Claire Bartlett; David M Clarke; Michael R Detty
Journal:  Bioorg Med Chem       Date:  2012-06-07       Impact factor: 3.641

2.  Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.

Authors:  Zachariah A McIver; Mark W Kryman; Young Choi; Benjamin N Coe; Gregory A Schamerhorn; Michelle K Linder; Kellie S Davies; Jacqueline E Hill; Geri A Sawada; Jason M Grayson; Michael R Detty
Journal:  Bioorg Med Chem       Date:  2016-06-02       Impact factor: 3.641

3.  Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors.

Authors:  Reza Dastvan; Smriti Mishra; Yelena B Peskova; Robert K Nakamoto; Hassane S Mchaourab
Journal:  Science       Date:  2019-05-17       Impact factor: 47.728

4.  HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Authors:  Gisela Caceres; Robert W Robey; Lubomir Sokol; Kathy L McGraw; Justine Clark; Nicholas J Lawrence; Said M Sebti; Michael Wiese; Alan F List
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

5.  Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity.

Authors:  Michael K Gannon; Jason J Holt; Stephanie M Bennett; Bryan R Wetzel; Tip W Loo; M Claire Bartlett; David M Clarke; Geri A Sawada; J William Higgins; Gregory Tombline; Thomas J Raub; Michael R Detty
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

6.  Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.

Authors:  Deep Agnani; Poulomi Acharya; Esteban Martinez; Thuy Thanh Tran; Feby Abraham; Frank Tobin; Harma Ellens; Joe Bentz
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

7.  Selenorhodamine photosensitizers for photodynamic therapy of P-glycoprotein-expressing cancer cells.

Authors:  Jacqueline E Hill; Michelle K Linder; Kellie S Davies; Geri A Sawada; Janet Morgan; Tymish Y Ohulchanskyy; Michael R Detty
Journal:  J Med Chem       Date:  2014-10-01       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.